TY - JOUR T1 - Selective antagonist reveals the role of prostaglandin receptor EP2 in cancer cell proliferation, invasion and inflammation JF - Journal of Pharmacology and Experimental Therapeutics JO - J Pharmacol Exp Ther DO - 10.1124/jpet.112.200444 SP - jpet.112.200444 AU - Jianxiong Jiang AU - Ray Dingledine Y1 - 2012/01/01 UR - http://jpet.aspetjournals.org/content/early/2012/11/28/jpet.112.200444.abstract N2 - Population studies, preclinical and clinical trials suggest a role for cyclooxygenase-2 (COX-2, PTGS2) in tumor formation and progression. The downstream prostanoid receptor signaling pathways involved in tumorigenesis are poorly understood, although prostaglandin E2 (PGE2), a major COX-2 metabolite in the involved tissues, presumably plays important roles in tumor biology. Taking advantage of our recently-identified novel antagonist for the EP2 (PTGER2) subtype of PGE2 receptor, we demonstrated that EP2 receptor activation promotes cancer cell growth and invasion in vitro, accompanied by upregulation of the tumor-promoting inflammatory cytokines. Our results indicate that selective block of PGE2-EP2 signaling pathway via small molecules might represent a novel therapy for tumorigenesis. ER -